Loomis Sayles & Co. L P Has $53.05 Million Position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

Loomis Sayles & Co. L P lessened its holdings in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 3.2% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,467,027 shares of the specialty pharmaceutical company’s stock after selling 49,096 shares during the quarter. Loomis Sayles & Co. L P owned 2.66% of Supernus Pharmaceuticals worth $53,048,000 as of its most recent SEC filing.

Other institutional investors have also recently bought and sold shares of the company. Barclays PLC boosted its position in shares of Supernus Pharmaceuticals by 88.3% during the third quarter. Barclays PLC now owns 108,788 shares of the specialty pharmaceutical company’s stock valued at $3,393,000 after buying an additional 51,005 shares during the last quarter. Geode Capital Management LLC lifted its stake in Supernus Pharmaceuticals by 5.3% during the 3rd quarter. Geode Capital Management LLC now owns 1,482,051 shares of the specialty pharmaceutical company’s stock valued at $46,218,000 after acquiring an additional 74,438 shares in the last quarter. Franklin Resources Inc. lifted its stake in Supernus Pharmaceuticals by 7.6% during the 3rd quarter. Franklin Resources Inc. now owns 29,981 shares of the specialty pharmaceutical company’s stock valued at $987,000 after acquiring an additional 2,121 shares in the last quarter. Empowered Funds LLC purchased a new position in Supernus Pharmaceuticals during the 4th quarter worth $1,498,000. Finally, Smartleaf Asset Management LLC grew its stake in shares of Supernus Pharmaceuticals by 219.1% in the 4th quarter. Smartleaf Asset Management LLC now owns 1,267 shares of the specialty pharmaceutical company’s stock worth $47,000 after acquiring an additional 870 shares in the last quarter.

Supernus Pharmaceuticals Stock Performance

SUPN opened at $32.42 on Friday. Supernus Pharmaceuticals, Inc. has a fifty-two week low of $25.53 and a fifty-two week high of $40.28. The firm has a 50-day moving average of $35.26 and a 200 day moving average of $35.02. The firm has a market cap of $1.81 billion, a P/E ratio of 30.30 and a beta of 0.83.

Insider Activity

In other Supernus Pharmaceuticals news, SVP Jonathan Rubin sold 927 shares of the stock in a transaction dated Friday, February 21st. The shares were sold at an average price of $39.15, for a total transaction of $36,292.05. Following the completion of the transaction, the senior vice president now owns 7,853 shares in the company, valued at $307,444.95. This trade represents a 10.56 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, VP Padmanabh P. Bhatt sold 9,477 shares of the business’s stock in a transaction that occurred on Tuesday, February 4th. The shares were sold at an average price of $39.70, for a total transaction of $376,236.90. Following the completion of the sale, the vice president now directly owns 10,149 shares in the company, valued at approximately $402,915.30. This trade represents a 48.29 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 11,104 shares of company stock valued at $440,263 in the last three months. Company insiders own 9.30% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on SUPN shares. Cantor Fitzgerald reissued a “neutral” rating and set a $36.00 price target on shares of Supernus Pharmaceuticals in a research report on Wednesday, February 26th. StockNews.com downgraded Supernus Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Monday.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.